And BPF, both of which are now known to have similar problems. It's not like the companies developing these chemicals don't know that they're likely to have th

And BPF, both of which are now known to have similar problems. It's not like the companies developing these chemicals don't know that they're likely to have the same activity. It's just pharmacology. Similar structures tend to have similar activity. I definitely second GPs suggestion of having the burden of proof reversed like that. It would greatly reduce the work required by researchers, too. Interestingly, BPA was actually known to have estrogenergic properties in the 30s shortly after it was first isolated, and was first researched as a potential estrogen replacement. With the right regulation this could have been caught close to a century ago...